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Introduction: Chronic hepatitis C is a leading cause of severe liver disease. Protease inhibitors used to treat these
patients are known to have many drug interactions, although there is limited data available between boceprevir
and warfarin. This case report is the first in vivo drug interaction reported in the literature.
Case presentation: A 73-year-old African American man was diagnosed with hepatitis C in 2004, and had decided
to not initiate therapy. In 2006, he was diagnosed with deep vein thrombosis and pulmonary embolism and was
started on warfarin. His international normalized ratio had been stable on a dose of 13.75mg to 20mg/week over a
period of 6 years. A liver biopsy in 2012 revealed marked fibrosis, leading the patient to start hepatitis C treatment
with peginterferon alfa-2a, ribavirin and boceprevir. Three weeks after starting boceprevir, his international normalized
ratio became subtherapeutic at 1.2. Upon increasing the warfarin dose by 16%, his international normalized ratio
remained at 1.2 6 days later. Two months after initiating boceprevir, he reached a therapeutic international normalized
ratio. His warfarin dose had been increased by 75% from his dose prior to starting boceprevir, from 15mg/week to
26.25mg/week. His hepatitis C treatment was discontinued at week 39 of the intended 48 weeks of treatment due to
severe thrombocytopenia. Upon discontinuation of boceprevir, his warfarin dose was prophylactically decreased by
17%, which resulted in a subtherapeutic international normalized ratio of 1.48 1 week later. The warfarin dose was
subsequently increased by 10% which resulted, 2 weeks later, in a therapeutic international normalized ratio of 2.8.
Once stabilized, his new warfarin dose was 23.75mg/week, 37% higher than his original maintenance dose of
15mg/week prior to starting boceprevir.
Conclusions: The co-administration of boceprevir and warfarin resulted in a subtherapeutic international normalized
ratio. Upon starting boceprevir, his warfarin dose was increased by 75% over 2 months to achieve a therapeutic
international normalized ratio. After discontinuing boceprevir, his maintenance dose of warfarin was 37% greater than
his original dose. This is an original case report which demonstrates the significant effects of this drug interaction and
the importance of monitoring international normalized ratio.
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Chronic hepatitis C virus (HCV) is an infection that af-
fects approximately 2.7 to 3.9 million people in the USA
with an estimated mortality rate of 12,000 deaths per
year according to the US Centers for Disease Control
and Prevention [1]. HCV is a progressive disease and
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ation. In acute cases of HCV infection, 75 to 85% will
become persistent, of which 20% will develop cirrhosis
after approximately 20-30 years [1].
There are reportedly six different genotypes of HCV in
the world, with genotype 1 being the most common in
the USA [1]. With the advent of HCV protease inhibitors
in addition to the standard regimen of pegylated inter-
feron and ribavirin, sustained virological response rates in
patients with chronic HCV genotype 1 have improved from
nearly 40 to 50% to approximately 60 to 80% [2].entral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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treatment of chronic HCV genotype 1. The mechanism
of action is a selective inhibition of the HCV NS3/4A
serine protease [3]. Dosing is 800mg every 8 hours, and
the duration of triple therapy with peginterferon and
ribavirin is dependent on the patient’s response to treat-
ment, which can vary between 24 to 48 weeks of treat-
ment [2,3]. There are many drug–drug interactions with
boceprevir, although to the best of our knowledge there
have not been any documented reports of an interaction
with warfarin. Here we present a probable interaction be-
tween boceprevir and warfarin.
Case presentation
The patient is a 73-year-old, 79kg African American
man with a past medical history of diabetes, hyperten-
sion, and microscopic hematuria. He was diagnosed with
HCV genotype 1a infection in 2004. At that time, he was
not interested in being treated with interferon and riba-
virin given poor response rates and profound adverse
effects. In June 2006, he was diagnosed with deep vein
thrombosis and pulmonary embolism, for which he was
started on warfarin and referred to the anticoagulation
clinic for drug monitoring. The duration of warfarin ther-
apy was determined to be indefinite by his primary care
team. His target international normalized ratio (INR) is 2
to 3, which had been stable on a warfarin dose of 13.75mg
to 20mg/week, over a period of 6 years.
He underwent a transjugular liver biopsy in April 2012
due to possible cirrhosis and for guidance of possible
HCV treatment. The biopsy showed mild fatty infiltration
of his liver and received a grade of stage F4 with marked
bridging fibrosis. At this time, he was interested in HCV
treatment. It was decided that he would begin treatment
with peginterferon alfa-2a weekly and ribavirin twice daily
for the first 4 weeks. Boceprevir would be added at week
five to be given every 8 hours for 44 weeks. He was infor-
med that treatment could be discontinued if he did
not demonstrate a positive and safe response to therapy.
Counseling on medication adverse effects and required
laboratory monitoring were reviewed with him.
HCV therapy with peginterferon alfa-2a and ribavirin
began on 1 August 2012. At this time, his INR was stable
on a weekly warfarin dose of 15mg for the previous 4
months. Boceprevir was scheduled to start on 29 August,
although he started it on 31 August. On the day prior to
starting boceprevir, his INR was 2.5. Five days after start-
ing boceprevir, his INR remained therapeutic at 2.5. On
19 September, almost 3 weeks later, his INR decreased to
1.2. He denied any missed doses of warfarin or changes in
consumption of vitamin K foods. His warfarin dose was
increased by 16% and 6 days later, on 25 September, his
INR remained subtherapeutic at 1.2. However, the day
before this visit, he had eaten a large portion of collardgreens, a high vitamin K food. The anticoagulation pro-
vider believed this may have contributed to the low INR.
Therefore, the provider instructed the patient to take
a booster dose and remain on the same weekly dose
of 17.5mg/week. At his following week’s appointment, his
INR was still subtherapeutic at 1.3 without any vitamin K
intake or missed doses of warfarin reported. He continued
to come to the anticoagulation clinic every 7 to 10 days
for INR monitoring and subsequent dose increases; see
Table 1 for more details. The majority of his INRs were
checked on a point-of-care (POC) device. Periodically, his
INRs were also checked in the laboratory through a
venipuncture blood draw. On two occasions, both a POC
and a laboratory INR were taken on the same day and
results correlated very well with one another.
He finally reached a therapeutic INR on 24 October
2012, almost 2 months after starting boceprevir. His ori-
ginal warfarin dose was increased by 75% from 15mg/
week to 26.25mg/week. In the subsequent weeks, his
INR trended downward due to an increased consump-
tion of vitamin K foods, for which his dose was further
increased to 30mg/week. At this point, his original dose
had doubled in order to maintain a therapeutic INR. For
approximately 2 months thereafter, he remained stable
on 30mg/week of warfarin. On 24 April 2013, his INR
increased to 3.6 while on 30mg/week of warfarin prob-
ably due to a decrease in vitamin K food intake. At this
point, his warfarin dose was reduced and his INR
returned to his therapeutic target by his next anticoagu-
lation clinic visit on 8 May 2013.
His HCV treatment was discontinued prematurely at
week 39 of the intended 48 weeks, due to severe throm-
bocytopenia. He had close follow-up in the Hepatitis C
clinic including complete blood count (CBC) monitoring
every 2 weeks. During his last week of therapy, his platelet
count decreased from 129,000 to 12,000. Of note, his ther-
apy had been complicated by multiple significant adverse
events including severe anemia with a hemoglobin nadir
of 7.8, and the development of two abscesses, a supra-
pubic and a facial abscess. The suprapubic abscess was
treated with a course of amoxicillin/clavulanic acid and
the facial abscess was treated with clindamycin. Amoxicil-
lin/clavulanic acid may increase the risk of bleeding when
given with warfarin but neither antibiotic should signifi-
cantly affect the INR [4]. His anemia had been difficult to
manage as he was unable to tolerate normal dosing ranges
of ribavirin. Approximately 7 weeks after starting ribavirin,
his dose was reduced to 1000mg/day. Two weeks later, it
was reduced again to 600mg/day and eventually down to
200mg/day. He continued to have CBC monitoring by the
Hepatitis C clinic with continual ribavirin adjustments.
His maintenance dose fluctuated from 200 to 800mg/day,
significantly less than his starting dose. Due to his anemia,
he required epoetin alfa supplementation throughout his
Table 1 Warfarin dosing relative to initiation and discontinuation of boceprevir
Date Weekly ribavirin dose (mg) Weekly warfarin dose (mg) POC-INR, LAB-INR* Important notes
11/07/2012 15 1.9
01/08/2012 1200 15 2.8 PEG-INF and RBV started
15/08/2012 1200 15 1.9
30/08/2012 1200 15 2.5
31/08/2012 1200 ----- ----- Boceprevir started
05/09/2012 1200 15 2.5
19/09/2012 1000 15 1.2
25/09/2012 1000 17.5 1.2 Consumed high vitamin K food
on 24/09/12
01/10/2012 600 17.5 1.3 Epoetin alfa and vitamin
B12 added
10/10/2012 600 20 1.3
16/10/2012 200 23.75 1.48*
24/10/2012 200 26.25 2.2
31/10/2012 200 26.25 1.72*
07/11/2012 200 27.5 2.0
14/11/2012 200 26.25 1.8 1.82* Patient took less warfarin than
instructed.
27/11/2012 400 27.5 2.24*
12/12/2012 600 27.5 2.0 2.02*
26/12/2012 800 28.75 2.1
16/01/2013 800 28.75 1.7
30/01/2013 800 31.25 2.0 Consumed high vitamin K food
twice in past week
13/02/2013 600 31.25 3.3
27/02/2013 200 30 2.4 Iron added
13/03/2013 400 30 2.9 Recent suprapubic abscess;
completing amoxicillin/clavulanate,
which started 07/03/13
27/03/2013 200 30 2.2
10/04/2013 200 30 2.4
24/04/2013 400 30 3.6 New facial abscess, starting 10-day
course clindamycin
08/05/2013 400 28.75 2.5 HCV medications DISCONTINUED
due to low platelets
16/05/2013 23.75 1.48*
29/05/2013 26.25 2.8
12/06/2013 Unknown 2.2 Hospitalized at outside hospital for UTI
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Abbreviations: HCV hepatitis C virus, INR international normalized ratio, LAB laboratory, PEG-INF peginterferon alfa-2a, POC point-of-care, RBV ribavirin, UTI urinary
tract infection. *Laboratory INR.
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cyanocobalamin. Fortunately, his HCV viral load had been
undetectable since week 10 of therapy. He did not experi-
ence any bleeding throughout his entire course. Given the
severity of his adverse events along with his improved viral
load, it was decided to discontinue HCV therapy as overall
risks outweighed benefits.
Upon discontinuing boceprevir, his warfarin dose was
prophylactically decreased by 17% anticipating that his
INR may start increasing. However, at his 1 week follow-
up visit, this caused his INR to decrease to 1.48. The
warfarin dose was subsequently increased by 10% which
resulted, 2 weeks later, in a therapeutic INR of 2.8. Over
the following several weeks, his warfarin dose was con-
tinuously adjusted. Upon stabilization of his INR, his
warfarin dosing needs decreased to 23.75mg/week. This
is a 21% reduction from his dose requirement of 26.25mg/
week while on boceprevir, and a 37% increase from his
original maintenance dose of 15mg/week prior to starting
boceprevir.
Discussion
Boceprevir is a HCV NS3/4A protease inhibitor approved
by the US Food and Drug Administration in 2011, for the
treatment of chronic HCV genotype 1 infection in com-
bination with peginterferon and ribavirin [3]. Boceprevir is
extensively metabolized in the liver, undergoing both
oxidation and reduction [3,4]. Despite a lack of in vivo
interaction studies between boceprevir and warfarin, the
manufacturer suggests warfarin concentrations may be
decreased or elevated by boceprevir, and the INR should
be monitored closely [3]. In vitro studies indicate bocepre-
vir is primarily metabolized by hepatic aldo-keto reductase
and partially metabolized by CYP3A4/5, and it is a potent
inhibitor of CYP3A4/5 [4,5]. Other major CYP450 en-
zymes, such as CYP1A2, 2C8, 2C9, and 2C19, have not
been found to be inhibited by boceprevir, although little to
no induction has been seen [6].
Warfarin, an oral anticoagulant, consists of a racemic
mixture of active enantiomers. Elimination occurs almost
exclusively by metabolism through CYP450 isozymes. The
S-enantiomer, which is more potent than the R-enantiomer,
is predominantly metabolized by the CYP2C9 isozyme,
whereas the R-enantiomer is primarily metabolized by
CYP1A2 and CYP3A4. Inhibitors and inducers of CYP2C9,
CYP1A2, and CYP3A4 are likely to result in increased anddecreased concentrations of warfarin, respectively [7]. Be-
cause boceprevir is a known inhibitor of CYP3A4, it is
expected to increase concentrations of warfarin, although
there is a possibility that boceprevir could also induce
CYP1A2 and CYP2C9 which would result in reduced con-
centrations of warfarin [4-6].
Although in vivo studies between boceprevir and war-
farin have not been reported, other interactions between
similar drugs have been documented. In one case report,
a patient starting telaprevir, along with ribavirin and
peginterferon alfa-2a, required an increase in the weekly
warfarin dose by 50% above baseline to re-attain a target
INR [8]. Similar to boceprevir, telaprevir has been shown
in in vitro studies to inhibit the metabolism of other drugs,
specifically substrates of CYP3A as well as P-glycoprotein
[8]. In both case reports including the one currently being
presented, telaprevir and boceprevir have demonstrated
an inhibition in warfarin activity, contrary to findings from
in vitro studies indicating such protease inhibitors act pri-
marily as inhibitors of metabolism resulting in increased
pharmacological activity [4,8].
Administration of human immunodeficiency virus (HIV)
protease inhibitors has shown interactions with warfarin
similar to those described in this case report between
boceprevir and warfarin. HIV protease inhibitors shown
to inhibit the activity of warfarin include lopinavir/ritona-
vir, nelfinavir/ritonavir, and saquinavir [9]. Although these
agents are primarily known as CYP450 inhibitors, as in
the case of boceprevir, they have demonstrated the ability
to decrease warfarin’s activity [9].
At each anticoagulation visit, our patient was assessed
for multiple factors that could contribute to variations in
INR. These factors included: changes in health, diet, alco-
hol use, tobacco use, renal function, and liver function.
Adherence to prescribed warfarin regimen and changes to
medications were also assessed at each visit. He denied
any missed doses of warfarin at each of his anticoagulation
clinic visits. If he had any potential contributing factors to
fluctuations in INR other than the addition of boceprevir,
it is documented under “Important notes” in Table 1.
He was newly started with peginterferon alfa-2a and
ribavirin 30 days prior to starting boceprevir. A literature
review has shown evidence that interferon may potentiate
the effect of warfarin, although this was not the effect seen
in our case report [10]. In the case of warfarin and ribavi-
rin, a drug interaction search using Micromedex® indicates
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review, a case report by Schulman reports an inhibition of
warfarin activity by ribavirin [12]. In Schulman’s report,
the interaction occurred immediately after initiation of
the antiviral therapy [12]. However, in our case report,
the INR did not decline until 7 weeks after ribavirin was
started. Furthermore, the dose of ribavirin was changed
frequently in the patient due to his anemia. Despite on-
going ribavirin dose changes, his INR did not change
significantly; see Table 1 for details. In another study,
ribavirin has been found to induce factor VII messenger
ribonucleic acid (mRNA) in patients with hemophilia
resulting in a reduction in bleeding episodes [13]. Due
to the lack of clear evidence of boceprevir inducing
CYP450 enzymes responsible for warfarin metabolism,
it is possible that the inhibition of warfarin activity may
be due to other unknown causes, such as in the case of
ribavirin inducing factor VII mRNA.
Approximately 1 month after starting boceprevir, our
patient was also started on epoetin alfa and cyanocobala-
min which are not known to interact with warfarin and
are unlikely causes for his decrease in INR [7,11]. Of note,
he did consume high vitamin K food beyond his normal
intake, prior to his 25 September 2012 visit, at which his
INR was subtherapeutic. High vitamin K-rich food can de-
crease the INR and therefore, may have been a contribut-
ing factor to his low INR [7]. However, his INR was also
low at his 19 September, 1 and 10 October visits at which
times he states he did not consume high vitamin K food.
The Naranjo probability scale for this case report indicates
a possible relationship between the interaction of bocepre-
vir and warfarin [14]. Ruling out other contributing fac-
tors, it appears his trend of subtherapeutic INRs was due
to the addition of boceprevir to his medication regimen.Conclusions
In this article, we present a case of a patient whose INR
decreased significantly after the start of boceprevir. His ori-
ginal warfarin dose was increased by 75% before reaching
therapeutic INR 2 months after starting boceprevir. From
our literature search, this is the first documented case re-
port regarding this drug interaction. Anticoagulation pro-
viders should be aware of this possible interaction and how
it can have significant effects on INR and, subsequently,
warfarin dosing. Close monitoring is recommended when
boceprevir is added to a medication regimen for a patient
also on warfarin.Consent
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